Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.
Eli Lilly will launch Mounjaro in India in 2025. The drug treats type 2 diabetes and obesity. Lilly received marketing ...
Novo Holdings’ $16.5 billion takeover of US contract development and manufacturing organisation (CDMO) Catalent does not ...
Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.
Eli Lilly, the US pharmaceutical giant that gained widespread attention globally with its weight-loss treatments, plans to ...
As demand for obesity drugs like Wegovy, Zepbound, Mounjaro and Ozempic, outpaces supply, online scams are rising, according to cybersecurity experts.
We recently compiled a list of the 10 Stocks Dominating a Billionaire Quant’s Investment Strategy. In this article, we are ...
Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...
In the fierce race to dominate the weight loss drug market, global pharmaceutical giant Eli Lilly announced on Wednesday that ...
Research shows an average weight loss of just 5% could save an annual $153bn in medical fees and lost productivity.